Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 6aldesleukin 6Cyclophosphamide 6fludarabine phosphate 5fludarabine 5Nivolumab 4durvalumab 3Sorafenib 3Radiotherapy 3Filgrastim 3Everolimus 3Axitinib 3Temozolomide 2Peripheral Blood Stem Cell Transplantation 2Isotretinoin 2Ipilimumab 2Interleukin-2 2Interferon-alpha 2Fluorouracil 2Dexamethasone 2Cyclosporine 2Bevacizumab 2vorolanib 1tremelimumab 1tocilizumab 1talazoparib 1spartalizumab 1sargramostim 1poly ICLC 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Kidney Neoplasms × guadecitabine × Clear all
NCT03308396 2022-02-17

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡